NATERA INC

Explore how Natera’s modest revenue growth, MRD acquisition, and AI‑driven digital pathology are driving the next wave of liquid biopsy diagnostics in oncology.

Sheena Jonathan’s 10b5‑1 share sale shows Natera’s strong governance and executive confidence, while highlighting market‑access, patent cliff risks and M&A growth prospects.

Sheena Jonathan sold 6,000 Natera shares under a Rule 10b‑5 plan, keeping prices stable and ownership unchanged—no shift in governance or market impact.

See how Natera’s Rule 10b‑5‑1 insider sales coincide with record‑high stock prices driven by earnings growth and analyst upgrades—an insider view of biotech’s upside.

Strong Natera earnings beat estimates, driving a 52‑week high and a new revenue outlook, fueled by growing oncology, transplant and reproductive‑health testing.

Strong Q2 2026 earnings: Natera cuts losses, boosts revenue and oncology test volumes, and upgrades 2026 revenue outlook to $1.08‑1.12 billion.

Explore how Natera’s Prospera cfDNA assay is set to transform kidney‑transplant monitoring in a groundbreaking Phase 3 study with Eledon, potentially reducing calcineurin use and improving long‑term graft outcomes.

Discover how a co‑founder’s insider sales at Natera (NTLA) signal strategic portfolio shifts and what they mean for investors in the high‑tech diagnostics market.

Discover how Natera’s board expansion, equity incentive plan boost and shareholder approvals reinforce governance, talent retention and investor confidence in biotech.

Corporate update: Natera, Inc. adds Thomas Lynch to its 12‑member board, details insider share sales, and confirms compliance with SEC filings.